Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / MIST - Week In Review: LianBio Acquires 2 IBD Candidates In $218 Million Deal

MIST - Week In Review: LianBio Acquires 2 IBD Candidates In $218 Million Deal

Milestone Pharmaceuticals Inc.
  • LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma.
  • Ji Xing Pharma of Shanghai acquired Greater China rights to a novel treatment for tachycardia from Milestone Pharma in a $127.5 million agreement.
  • Singapore's Hummingbird Bioscience closed a $125 million Series C financing round led by Novo Holdings.

For further details see:

Week In Review: LianBio Acquires 2 IBD Candidates In $218 Million Deal
Stock Information
Company Name: Milestone Pharmaceuticals Inc.
Stock Symbol: MIST
Market: NYSE
Website: milestonepharma.com
Menu
MIST MIST Quote MIST Short MIST News MIST Articles MIST Message Board
Get MIST Alerts

News, Short Squeeze, Breakout and More Instantly...